You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: WinSanTor, Inc. Topic: NCI
PROJECT SUMMARY Chemotherapy induced peripheral neuropathyCIPNis a debilitating condition that afflictsof cancer patients undergoing chemotherapy and limits the dose and duration of treatmentSymptoms range from sensory loss to painful neuropathy and are accompanied by electrophysiological and structural indices of nerve damageThe American Society of Clinical Oncology currently makes no recommendat ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: ATGC Inc. Topic: 100
Abstract Applications of customizable nucleases such as CRISPRclustered regularly interspaced short palindromic repeatsCasCRISPR associated proteinhave enabled efficient and precise gene correction in vitroand hold promises for eventually achieving in vivo gene correction therapyHoweverto apply CRISPR Casin therapeutic settingsseveral major challenges remain to be addressedihomologous recombinatio ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: EPPIN PHARMA INC Topic: NICHD
The global contraceptives market was valued at $billion inand is expected to grow at a CAGR offromtoto reach an estimated value of $billion inThe contraceptive market consists of short term methods such as condoms and oral contraceptionlong term methods including implants and IUDsand permanent methods such as tubal ligations and vasectomiesEppin Pharmaandapos s product has a unique set of characte ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: PROTEIN METRICS INC Topic: 400
Project SummaryGlycosylation is one of the most prevalent and important post translational modifications of proteinsyet it is also one of the most difficult to studyNo single method nor analytical platform can give complete information about the glycosylation in a protein sampleand the analytical methods in current use include both ESI and MALDI single and tandem mass spectrometryat least four typ ...STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
SBC: CELL MICROSYSTEMS INC Topic: NIAID
Project SummaryAdoptive cell therapyACTis an emerging immunotherapy which shows significant promise in treating both leukemia and solid tumorsas well as certain infectious diseasesACT comprises the isolation and ex vivo expansion of cytotoxic T lymphocytesCTLsrecognizing epitopes of a mutated or aberrantly expressed protein present almost exclusively on the surface of a patient s tumor cellsTo mee ...STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
SBC: REMD BIOTHERAPEUTICS INC. Topic: NIDDK
DESCRIPTIONprovided by applicantFast TrackInsulin remains the primaryand often the onlytreatment for typediabetes mellitusT DHowever it is associated with chronic iatrogenic hyperinsulinemiasecondary hyperlipidemiahigher incidence and severity of cardiovascular complicationsand life threatening hypoglycemia eventsA higher mortalityvsdue to cardiovascular complications were reported in insulin trea ...STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
SBC: L2 DIAGNOSTICS LLC Topic: N/A
DESCRIPTION (provided by applicant): Breast cancer remains one of the most insidious and difficult to treat human malignancies, affecting thousands of individuals each year. Our proposed studies are aimed at developing a novel tumor immunotherapy by using cryptic peptides of Her-2 protein and modified Her-2 peptides, both of which break immune tolerance to ?self? tumor antigens expressed on breast ...STTR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
SBC: CBT4CBT LLC Topic: R42
The goal of this fast track STTR proposal is to expand buprenorphine maintenance therapy for opioiddependent patientsOvermillion people in the US are addicted to opiatesProviding effective agonist therapymethadone or buprenorphinecoupled with behavioral counseling greatly improves outcomesreduces morbidityand reduces societal costsMethadone maintenance treatment has been limited due to complex sta ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health